Cannabis Science Set to Integrate Its Sponsored Research In Nigeria to Include Its U.S. Patent Number 9,763,991 for Compositions of Cannabinol (CBN) for Treatment of Various Neurological Conditions

Available Files

No files uploaded.

Robert Kane Monday, 25 February 2019 06:45



Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that it intends to expand the scope of its sponsored research in Nigeria to include neurological conditions, including Post-Traumatic Stress Disorder (PTSD). CBIS and its research collaborator are currently investigating the potential beneficial effects of cannabidiol on oro-bucco-lingual dyskinesias, oxidative stress, and psychosis using animal studies and a clinical trial. 




See the full press release here;

https://www.otcmarkets.com/stock/CBIS/news/story?e&id=1293381


Loading content, please wait.

Become an iCannabinoid Ambassador

GET INV

Observational Studies

PART

Activity Stream

Osaruname Osayi-Osazuwa shared Raymond C. Dabney's status 6 days ago

Attending the GHC Summit is how I got involved with iCannabinoid. I had just finished my Masters thesis about prescription drug abuse and misuse and the rest is history.

Next month May 24-26 is the 2019 Harvard GHC Summit !!

Our team will be be attending for the 3rd year in a row and are very excited as every year it...
Show more

The Company is in the process of getting a third-party, independent valuation to establish the value of its CBN patent for the Canadian, U.S.,... Show more

Notifications

Events

Sorry, we currently have no events.
View All Events